Wells Fargo
ARQT icon

Wells Fargo’s Arcutis Biotherapeutics ARQT Stock Holding History

Wells Fargo’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.86M Sell
109,079
-88,731
-45% -$2.07M ﹤0.01% 3316
2026
Q1 		$4.66M Sell
197,810
-86,433
-30% -$2.21M ﹤0.01% 2649
2025
Q4 		$8.25M Buy
284,243
+178,986
+170% +$4.58M ﹤0.01% 2216
2025
Q3 		$1.98M Sell
105,257
-91,043
-46% -$1.44M ﹤0.01% 3309
2025
Q2 		$2.75M Sell
196,300
-2,059
-1% -$28.9K ﹤0.01% 2948
2025
Q1 		$3.1M Buy
198,359
+145,904
+278% +$2.06M ﹤0.01% 2793
2024
Q4 		$731K Buy
52,455
+16,682
+47% +$183K ﹤0.01% 3929
2024
Q3 		$333K Sell
35,773
-792
-2% -$7.82K ﹤0.01% 4262
2024
Q2 		$340K Buy
36,565
+8,807
+32% +$79.6K ﹤0.01% 4161
2024
Q1 		$275K Buy
27,758
+6,144
+28% +$45.9K ﹤0.01% 4270
2023
Q4 		$69.8K Sell
21,614
-65,164
-75% -$177K ﹤0.01% 5120
2023
Q3 		$461K Sell
86,778
-19,972
-19% -$170K ﹤0.01% 3838
2023
Q2 		$1.02M Buy
106,750
+44,115
+70% +$490K ﹤0.01% 3464
2023
Q1 		$689K Buy
62,635
+59,195
+1,721% +$856K ﹤0.01% 3631
2022
Q4 		$50.9K Sell
3,440
-422
-11% -$7.37K ﹤0.01% 4846
2022
Q3 		$73K Buy
3,862
+196
+5% +$4.44K ﹤0.01% 4763
2022
Q2 		$78K Sell
3,666
-135,069
-97% -$2.77M ﹤0.01% 4784
2022
Q1 		$2.67M Sell
138,735
-2,827
-2% -$47.8K ﹤0.01% 3019
2021
Q4 		$2.94M Sell
141,562
-631,652
-82% -$12.6M ﹤0.01% 3109
2021
Q3 		$18.5M Sell
773,214
-124,758
-14% -$2.85M ﹤0.01% 1720
2021
Q2 		$24.5M Buy
897,972
+21,388
+2% +$602K 0.01% 1533
2021
Q1 		$25.4M Buy
876,584
+233,128
+36% +$7.28M 0.01% 1479
2020
Q4 		$18.1M Buy
643,456
+87,093
+16% +$2.13M ﹤0.01% 1628
2020
Q3 		$16.3M Buy
556,363
+29,236
+6% +$781K ﹤0.01% 1544
2020
Q2 		$15.9M Buy
527,127
+113,356
+27% +$3.28M ﹤0.01% 1508
2020
Q1 		$12.3M Buy
+413,771
New +$11.1M ﹤0.01% 1535

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wells Fargo's ARQT Position: Q2 2026 in Review

Wells Fargo reduced its Arcutis Biotherapeutics (ARQT) stake by 45% in Q2 2026, selling an estimated $2.07M and leaving 109,079 shares worth $2.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3316.

Wells Fargo first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $25.4M in Q1 2021. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Wells Fargo held 109,079 shares of Arcutis Biotherapeutics worth $2.86M as of Q2 2026.
  • Wells Fargo sold 88,731 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.07M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3316 holding.
  • Wells Fargo first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Wells Fargo's Arcutis Biotherapeutics position peaked at $25.4M in Q1 2021.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.